Simultaneous hepatitis B, C and HIV screening with rapid tests and FibroScan for people who use drugs and other vulnerable adults outside hospitals
Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®
This project will try offering rapid blood tests and on-site FibroScan to find hepatitis B, C and HIV and quickly link people who use drugs and other vulnerable adults to care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Limoges Academic / other |
| Locations | 1 site (Limoges) |
| Trial ID | NCT06904820 on ClinicalTrials.gov |
What this trial studies
The SCANVIR approach brings simultaneous rapid testing for hepatitis B, C and HIV plus on-site liver stiffness measurement (FibroScan) to non-traditional care settings such as addiction centers and harm-reduction sites. It uses dedicated screening days to test, start treatment when possible, and follow up people who inject drugs (PWIDs) and other vulnerable groups who often miss usual care pathways. The project is observational and focuses on feasibility, acceptability and reproducibility of this ‘‘test, treat and cure’’ model initially implemented across several French departments. Enrollment is limited to adults (18+) attending designated outside-the-walls sites or referred by care professionals who do not object to research.
Who should consider this trial
Good fit: Adults (18+) who use drugs or belong to vulnerable populations and who attend designated non-traditional care sites or are referred by professionals, and who do not oppose participation in research.
Not a fit: People under 18, those who refuse participation, or individuals already engaged in regular hepatitis care or already cured are unlikely to gain added benefit from this program.
Why it matters
Potential benefit: If successful, this approach could increase diagnosis and rapid treatment initiation for hepatitis C and related infections in hard-to-reach populations, reducing future liver disease and transmission.
How similar studies have performed: Community-based test-and-treat programs for hepatitis C among PWIDs have shown promising improvements in diagnosis and treatment uptake, so this approach builds on prior successful models.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult 18 and over * Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector * Patient not opposed to research Exclusion Criteria: * Age under 18 * Patient opposed to research
Where this trial is running
Limoges
- Limoges University Hospital — Limoges, France (Recruiting)
Study contacts
- Principal investigator: marilyne DEBETTE-GRATIEN, MD — University Hospital, Limoges
- Study coordinator: Marilyne DEBETTE-GRATIEN, MD
- Email: marilyne.gratien@chu-limoges.fr
- Phone: +33555056604
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.